Daily intermittent fasting in mice enhances morphine-induced antinociception while mitigating reward, tolerance, and constipation
AffiliationUniv Arizona, Coll Med, Dept Pharmacol
MetadataShow full item record
PublisherLIPPINCOTT WILLIAMS & WILKINS
CitationDuron, David I.; Hanak, Filip; Streicher, John M. Daily intermittent fasting in mice enhances morphine-induced antinociception while mitigating reward, tolerance, and constipation, PAIN: October 2020 - Volume 161 - Issue 10 - p 2353-2363 doi: 10.1097/j.pain.0000000000001918
RightsCopyright © 2020 International Association for the Study of Pain.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractThe opioid epidemic has plagued the United States with high levels of abuse and poor quality of life for chronic pain patients requiring continuous use of opioids. New drug discovery efforts have been implemented to mitigate this epidemic; however, new medications are still limited by low efficacy and/or high side effect and abuse potential. Intermittent fasting (IF) has recently been shown to improve a variety of pathological states, including stroke and neuroinflammation. Numerous animal and human studies have shown the benefits of IF in these disease states, but not in pain and opioid treatment. We thus subjected male and female CD-1 mice to 18-hour fasting intervals followed by 6-hour feed periods with standard chow for 1 week. Mice that underwent this diet displayed an enhanced antinociceptive response to morphine both in efficacy and duration using thermal tail-flick and postoperative paw incision pain models. While showing enhanced antinociception, IF mice also demonstrated no morphine reward and reduced tolerance and constipation. Seeking a mechanism for these improvements, we found that the mu-opioid receptor showed enhanced efficacy and reduced tolerance in the spinal cord and periaqueductal gray, respectively, from IF mice using a(35)S-GTP gamma S coupling assay. These improvements in receptor function were not due to changes in mu-opioid receptor protein expression. These data suggest that a daily IF diet may improve the therapeutic index of acute and chronic opioid therapies for pain patients in the clinic, providing a novel tool to improve patient therapy and reduce potential abuse.
Note12 month embargo; published 01 October 2020
VersionFinal accepted manuscript
- Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors.
- Authors: Smith PA, Selley DE, Sim-Selley LJ, Welch SP
- Issue date: 2007 Oct 1
- Inhibition of Gβγ-subunit signaling potentiates morphine-induced antinociception but not respiratory depression, constipation, locomotion, and reward.
- Authors: Hoot MR, Sypek EI, Reilley KJ, Carey AN, Bidlack JM, McLaughlin JP
- Issue date: 2013 Apr
- Alterations in nociception and morphine antinociception in mice fed a high-fat diet.
- Authors: Nealon CM, Patel C, Worley BL, Henderson-Redmond AN, Morgan DJ, Czyzyk TA
- Issue date: 2018 Apr
- Positive Allosteric Modulation of CB<sub>1</sub> Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward.
- Authors: Slivicki RA, Iyer V, Mali SS, Garai S, Thakur GA, Crystal JD, Hohmann AG
- Issue date: 2020
- MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate], a derivative of the indole alkaloid mitragynine: a novel dual-acting mu- and kappa-opioid agonist with potent antinociceptive and weak rewarding effects in mice.
- Authors: Matsumoto K, Takayama H, Narita M, Nakamura A, Suzuki M, Suzuki T, Murayama T, Wongseripipatana S, Misawa K, Kitajima M, Tashima K, Horie S
- Issue date: 2008 Aug